[HTML][HTML] MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma
L Castillo, AIJ Young, A Mawson, P Schafranek… - Oncogene, 2020 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is
phenotypically heterogeneous with a highly unstable genome and provides few common …
phenotypically heterogeneous with a highly unstable genome and provides few common …
Choline Kinase Alpha (CHKα) as a therapeutic target in pancreatic ductal adenocarcinoma: Expression, predictive value, and sensitivity to inhibitors
JM Mazarico, VJ Sanchez-Arevalo Lobo… - Molecular cancer …, 2016 - AACR
Choline kinase α (CHKα) plays a crucial role in the regulation of membrane phospholipid
synthesis and has oncogenic properties in vitro. We have analyzed the expression of CHKα …
synthesis and has oncogenic properties in vitro. We have analyzed the expression of CHKα …
[HTML][HTML] Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to limited therapeutic
options and expensive/burdensome drug discovery processes. Utilizing genomic-data …
options and expensive/burdensome drug discovery processes. Utilizing genomic-data …
Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460
XX Zhu, JH Li, X Ni, X Wu, X Hou, YX Li, SJ Li… - Cancer …, 2022 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with extremely poor
prognosis. Gemcitabine resistance is a major challenge in the treatment of PDAC. Here, we …
prognosis. Gemcitabine resistance is a major challenge in the treatment of PDAC. Here, we …
[HTML][HTML] MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib
AIJ Young, AMK Law, L Castillo, S Chong… - Breast Cancer …, 2016 - Springer
Background Metastatic disease is largely resistant to therapy and accounts for almost all
cancer deaths. Myeloid cell leukemia-1 (MCL-1) is an important regulator of cell survival and …
cancer deaths. Myeloid cell leukemia-1 (MCL-1) is an important regulator of cell survival and …
[HTML][HTML] Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal …
Y Okada, S Nishiwada, K Yamamura, M Sho… - European Journal of …, 2021 - Elsevier
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal
malignancies. While the extracellular matrix component plays an integral role in PDAC …
malignancies. While the extracellular matrix component plays an integral role in PDAC …
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma
JP Morton, SA Karim, K Graham, P Timpson… - Gastroenterology, 2010 - Elsevier
BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a highly invasive and
metastatic disease for which conventional treatments are of limited efficacy. A number of …
metastatic disease for which conventional treatments are of limited efficacy. A number of …
[HTML][HTML] Targeting mTOR in pancreatic ductal adenocarcinoma
S Iriana, S Ahmed, J Gong, AA Annamalai, R Tuli… - Frontiers in …, 2016 - frontiersin.org
Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited;
however, new therapies targeting specific tumor-related molecular characteristics may help …
however, new therapies targeting specific tumor-related molecular characteristics may help …
[HTML][HTML] Advances in pancreatic ductal adenocarcinoma treatment
EM Anderson, S Thomassian, J Gong, A Hendifar… - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic cancer remains one of the most challenging malignancies to
treat with standard approaches. Emerging treatment approaches incorporating innovative …
treat with standard approaches. Emerging treatment approaches incorporating innovative …
BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine
AL Miller, SC Fehling, RB Vance, D Chen, EJ Brown… - Cancer Letters, 2024 - Elsevier
Efforts to develop targetable molecular bases for drug resistance for pancreatic ductal
adenocarcinoma (PDAC) have been equivocally successful. Using RNA-seq and ingenuity …
adenocarcinoma (PDAC) have been equivocally successful. Using RNA-seq and ingenuity …